Personalized medicine in diabetes mellitus: Current opportunities and future prospects

Annals of the New York Academy of Sciences

Volumn 1346, Issue 1, 2015, Pages 45-56

  Kleinberger, Jeffrey W ^a   Pollin, Toni I ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Monogenic diabetes; Pharmacogenetics, gene environment interaction; Pharmacogenomics; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AQUAPORIN 2; AUTOANTIBODY; C PEPTIDE; CHYMOTRYPSIN; CYTOCHROME P450 2C8; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HEPATIC NUCLEAR FACTOR 1ALPHA; HEPATIC NUCLEAR FACTOR 4ALPHA; IA ANTIBODY; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC; ZINC TRANSPORTER; ZINC TRANSPORTER 8; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FLUID RETENTION; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOTE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW DRUG DOSE; MINERAL SUPPLEMENTATION; MONOGENIC DIABETES; MONOGENIC DISORDER; NEONATAL DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTIVE VALUE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; TREATMENT RESPONSE; DIABETES MELLITUS, TYPE 2; GENETICS; LIFESTYLE; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; TRENDS;

ADMINISTRATION, ORAL; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; GENE-ENVIRONMENT INTERACTION; GENETIC TESTING; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PHARMACOGENETICS; PRECISION MEDICINE;

EID: 84949110261     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12757     Document Type: Article

References (82)

1. Turner, R.C., C.A. Cull, V. Frighi, et al. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281: 2005-2012.
2. Riedel, A.A., H. Heien, J. Wogen, et al. 2007. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27: 1102-1110.
3. Chiang, J.L., M.S. Kirkman, L.M. Laffel, et al. 2014. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diab. Care 37: 2034-2054.
4. Lebovitz, H.E. 2010. Adjunct therapy for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6: 326-334.
5. Pociot, F., B. Akolkar, P. Concannon, et al. 2010. Genetics of type 1 diabetes: what's next? Diabetes 59: 1561-1571.
6. American Diabetes Association. 2015. (2) Classification and diagnosis of diabetes. Diabetes Care 38(Suppl): S8-S16.
7. Hara, K., N. Shojima, J. Hosoe, et al. 2014. Genetic architecture of type 2 diabetes. Biochem. Biophys. Res. Commun. 452: 213-220.
8. Shepherd, M., B. Shields, S. Ellard, et al. 2009. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet. Med. 26: 437-441.
9. Hattersley, A., J. Bruining, J. Shield, et al. 2009. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr. Diab. 10(Suppl 12): 33-42.
10. Bellanne-Chantelot, C., D.J. Levy, C. Carette, et al. 2011. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J. Clin. Endocrinol. Metab. 96: E1346-E1351.
11. Shields, B.M., S. Hicks, M.H. Shepherd, et al. 2010. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53: 2504-2508.
12. Boj, S.F., D. Petrov & J. Ferrer. 2010. Epistasis of transcriptomes reveals synergism between transcriptional activators Hnf1alpha and Hnf4alpha. PLoS Genet. 6: e1000970.
13. Pearson, E.R., W.G. Liddell, M. Shepherd, et al. 2000. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diab. Med. 17: 543-545.
14. Jesic, M.D., S. Sajic, M.M. Jesic, et al. 2008. A case of new mutation in maturity-onset diabetes of the young type 3 (MODY 3) responsive to a low dose of sulphonylurea. Diab. Res. Clin. Pract. 81: e1-e3.
15. Boileau, P., C. Wolfrum, D.Q. Shih, et al. 2002. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). Diabetes 51(Suppl 3): S343-S348.
16. Vionnet, N., M. Stoffel, J. Takeda, et al. 1992. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 356: 721-722.
17. Ajjan, R.A. & K.R. Owen. 2014. Glucokinase MODY and implications for treatment goals of common forms of diabetes. Curr. Diab. Rep. 14: 559-014-0559-0.
18. Clement, K., M.E. Pueyo, M. Vaxillaire, et al. 1996. Assessment of insulin sensitivity in glucokinase-deficient subjects. Diabetologia. 39: 82-90.
19. Ellard, S., F. Beards, L.I. Allen, et al. 2000. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia 43: 250-253.
20. Shehadeh, N., D. Bakri, P.R. Njolstad, et al. 2005. Clinical characteristics of mutation carriers in a large family with glucokinase diabetes (MODY2). Diabet. Med. 22: 994-998.
21. Shields, B.M., G. Spyer, A.S. Slingerland, et al. 2008. Mutations in the glucokinase gene of the fetus result in reduced placental weight. Diab. Care 31: 753-757.
22. Flanagan, S.E., S. Clauin, C. Bellanne-Chantelot, et al. 2009. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat. 30: 170-180.
23. Dupont, J., C. Pereira, A. Medeira, et al. 2012. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas. J. Pediatr. Endocrinol. Metab. 25: 367-370.
24. Siklar, Z., S. Ellard, E. Okulu, et al. 2011. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant. J. Pediatr. Endocrinol. Metab. 24: 1077-1080.
25. Pearson, E.R., I. Flechtner, P.R. Njolstad, et al. 2006. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med. 355: 467-477.
26. Pihoker, C., L.K. Gilliam, S. Ellard, et al. 2013. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J. Clin. Endocrinol. Metab. 98: 4055-4062.
27. Ellard, S., H. Lango Allen, E. De Franco, et al. 2013. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 56: 1958-1963.
28. Bonnefond, A., J. Philippe, E. Durand, et al. 2014. Highly sensitive diagnosis of 43 monogenic forms of diabetes or obesity through one-step PCR-based enrichment in combination with next-generation sequencing. Diab. Care 37: 460-467.
29. Carroll, R.W. & R. Murphy. 2013. Monogenic diabetes: a diagnostic algorithm for clinicians. Genes (Basel) 4: 522-535.
30. Pinelli, M., F. Acquaviva, F. Barbetti, et al. 2013. Identification of candidate children for maturity-onset diabetes of the young type 2 (MODY2) gene testing: a seven-item clinical flowchart (7-iF). PLoS One 8: e79933.
31. Fajans, S.S. & G.I. Bell. 2011. MODY: history, genetics, pathophysiology, and clinical decision making. Diab. Care 34: 1878-1884.
32. Stein, S.A., K.L. Maloney & T.I. Pollin. 2014. Genetic counseling for diabetes mellitus. Curr. Genet. Med. Rep. 2: 56-67.
33. Ellard, S., C. Bellanne-Chantelot, A.T. Hattersley, et al. 2008. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51: 546-553.
34. McDonald, T.J., K. Colclough, R. Brown, et al. 2011. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet. Med. 28: 1028-1033.
35. Jones, A.G. & A.T. Hattersley. 2013. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diab. Med. 30: 803-817.
36. American Diabetes Association. 2014. Standards of medical care in diabetes-2014. Diab. Care 37: S14-S80.
37. van Leeuwen, N., G. Nijpels, M.L. Becker, et al. 2012. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 55: 1971-1977.
38. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, K. Zhou, et al. 2011. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet. 43: 117-120.
39. Florez, J.C., K.A. Jablonski, A. Taylor, et al. 2012. The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diab. Care 35: 1864-1867.
40. Graham, G.G., J. Punt, M. Arora, et al. 2011. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50: 81-98.
41. Shu, Y., C. Brown, R.A. Castro, et al. 2008. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther. 83: 273-280.
42. Shu, Y., S.A. Sheardown, C. Brown, et al. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117: 1422-1431.
43. Tzvetkov, M.V., S.V. Vormfelde, D. Balen, et al. 2009. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther. 86: 299-306.
44. Zhou, K., L.A. Donnelly, C.H. Kimber, et al. 2009. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 58: 1434-1439.
45. Jablonski, K.A., J.B. McAteer, P.I. de Bakker, et al. 2010. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 59: 2672-2681.
46. Becker, M.L., L.E. Visser, R.H. van Schaik, et al. 2009. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 58: 745-749.
47. Inagaki, N., T. Gonoi, J.P. Clement 4th, et al. 1995. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166-1170.
48. Florez, J.C., K.A. Jablonski, S.E. Kahn, et al. 2007. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 56: 531-536.
49. Lang, V.Y., M. Fatehi & P.E. Light. 2012. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenet. Genom. 22: 206-214.
50. Sato, R., H. Watanabe, R. Genma, et al. 2010. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics 11: 1743-1750.
51. Sesti, G., E. Laratta, M. Cardellini, et al. 2006. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91: 2334-2339.
52. Pearson, E.R., L.A. Donnelly, C. Kimber, et al. 2007. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56: 2178-2182.
53. Sesti, G., M.A. Marini, M. Cardellini, et al. 2004. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diab. Care 27: 1394-1398.
54. Holstein, A., A. Plaschke, M. Ptak, et al. 2005. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol. 60: 103-106.
55. Zhou, K., L. Donnelly, L. Burch, et al. 2010. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 87: 52-56.
56. McLeod, J.F. 2004. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin. Pharmacokinet. 43: 97-120.
57. Kalliokoski, A., M. Neuvonen, P.J. Neuvonen, et al. 2008. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J. Clin. Pharmacol. 48: 311-321.
58. Cheng, Y., G. Wang, W. Zhang, et al. 2013. Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers. Eur. J. Clin. Pharmacol. 69: 407-413.
59. Yu, W., C. Hu, R. Zhang, et al. 2011. Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clin. Pharmacol. Ther. 89: 437-442.
60. Kirchheiner, J., I. Meineke, G. Muller, et al. 2004. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin. Pharmacokinet. 43: 267-278.
61. Tomalik-Scharte, D., U. Fuhr, M. Hellmich, et al. 2011. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab. Dispos. 39: 927-932.
62. Yokoi, T. 2010. Troglitazone. Handb. Exp. Pharmacol. 196: 419-35. doi: 419-435.
63. Singh, S., Y.K. Loke & C.D. Furberg. 2007. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298: 1189-1195.
64. Lewis, J.D., A. Ferrara, T. Peng, et al. 2011. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diab. Care 34: 916-922.
65. Chang, T.J., P.H. Liu, Y.C. Liang, et al. 2011. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes. Pharmacogenet. Genom. 21: 829-836.
66. Kang, E.S., S.Y. Park, H.J. Kim, et al. 2005. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin. Pharmacol. Ther. 78: 202-208.
67. Chen, M., C. Hu, R. Zhang, et al. 2014. Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients. Pharmacogenom. J. 14: 488-492.
68. Hruska, M.W., J.A. Amico, T.Y. Langaee, et al. 2005. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br. J. Clin. Pharmacol. 59: 70-79.
69. Nauck, M.A. 2011. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am. J. Med. 124: S3-18.
70. 't Hart, L.M., A. Fritsche, G. Nijpels, et al. 2013. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 62: 3275-3281.
71. Hertel, J.K., S. Johansson, H. Raeder, et al. 2008. Genetic analysis of recently identified type 2 diabetes loci in 1638 unselected patients with type 2 diabetes and 1858 control participants from a Norwegian population-based cohort (the HUNT study). Diabetologia 51: 971-977.
72. Patel, C.J., R. Chen, K. Kodama, et al. 2013. Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. Hum. Genet. 132: 495-508.
73. Maruthur, N.M., J.M. Clark, M. Fu, et al. 2014. Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia 58: 295-303.
74. Flannick, J., G. Thorleifsson, N.L. Beer, et al. 2014. Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat. Genet. 46: 357-363.
75. Pollin, T.I., C.M. Damcott, H. Shen, et al. 2008. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322: 1702-1705.
76. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, J. Crosby, G.M. Peloso, et al. 2014. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371: 22-31.
77. Fitzgerald, K., A. Borodovsky, W. Querbes, et al. 2014. Abstract 7: a subcutaneous, potent and durable RNAi platform targeting metabolic diseases, genes PCSK9, ApoC3 and ANGPLT3. Arterioscler. Thromb. Vasc. Biol. 34: A7-A7.
78. Florez, J.C., K.A. Jablonski, N. Bayley, et al. 2006. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355: 241-250.
79. Moore, A.F., K.A. Jablonski, J.B. McAteer, et al. 2008. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes 57: 2503-2510.
80. Laaksonen, D.E., N. Siitonen, J. Lindstrom, et al. 2007. Physical activity, diet, and incident diabetes in relation to an ADRA2B polymorphism. Med. Sci. Sports Exerc. 39: 227-232.
81. Franks, P.W. 2011. Gene x environment interactions in type 2 diabetes. Curr. Diab Rep. 11: 552-561.
82. Franks, P.W., E. Pearson & J.C. Florez. 2013. Gene-environment and gene-treatment interactions in type 2 diabetes: progress, pitfalls, and prospects. Diab. Care 36: 1413-1421.